Eli Lilly's Donanemab Slows Alzheimer's Progression in Clinical Trial.

Eli Lilly's Alzheimer's treatment, donanemab, significantly slowed the progression of the disease in patients who received monthly antibody infusions during an 18-month study, according to clinical trial data. Patients who took donanemab were 39% less likely to progress to the next stage of the disease during the study. However, the treatment's benefits will have to be weighed against the risk of brain swelling and bleeding that can be serious and even fatal in rare cases. Lilly plans to apply for FDA approval of donanemab as soon as this quarter.